Business
PacBio to Report Third Quarter Earnings on November 7 and Host Inaugural Investor Day on November 15
Withdraws Guidance with New Product Announcement MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its
About this update from Pacific Biosciences Of California, Inc.
[{"type":"text","content":"Withdraws Guidance with New Product Announcement \nMENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, Nov. 7, 2022, at 5:00 p.m. Eastern Time.\n\n \n \n \n \n \n \n\n \nPacBio will also host its Inaugural Investor Day on Tuesday, Nov. 15, 2022, at 8:00 a.m. Eastern Time. The event will feature presentations by members of PacBio's executive team and include Q&A sessions.\nBoth events will be webcast live and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/.\nThird Quarter Earnings DetailsDate: Monday, Nov. 7, 2022 at 5:00 p.m. ET (2:00 p.m. PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 866-652-5200International: 412-317-6060\nIf using the dial-in option, please dial into the call five to ten minutes prior to start time using the appropriate number above and ask to join the \"PacBio Q3 Earnings Call.\"\nPacBio 2022 Investor Day Details Date: Tuesday, Nov. 15, 2022 at 8:00 a.m. ET (5:00 a.m. PT)Location: The St. Regis Hotel, Two E 55th Street, New York, NY 10022Listen via internet or replay: https://investor.pacificbiosciences.com/\n2022 Financial GuidanceIn light of forthcoming product announcements, we are withdrawing all prior financial guidance. We plan to provide additional information during our third quarter earnings call on Nov. 7, 2022.\nAbout PacBioPacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB™ short read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.\nPacBio products are provided for Research Use Only. Not for use i...